Literature DB >> 29752284

Analysis of the thrombotic and fibrinolytic activities of tumor cell-derived extracellular vesicles.

Ludovic Durrieu1, Alamelu Bharadwaj1, David M Waisman1,2.   

Abstract

Exosomes and microvesicles (MVs) are small extracellular vesicles secreted by tumor cells and are suggested to contribute to the thrombotic events that commonly occur in patients with advanced malignancies. Paradoxically, these vesicles have been reported to also possess fibrinolytic activity. To determine whether thrombotic or fibrinolytic activity is a predominant characteristic of these extracellular vesicles, we prepared exosomes and MVs from 2 breast cancer cell lines (MDA-MB-231 and MCF7), a lung cancer cell line (A549), and a leukemia cell line (NB4) and assayed their thrombotic and fibrinolytic activities. We observed that thrombotic activity was a common feature of MVs but not exosomes. Exosomes and/or MVs from several cell lines, with the exception of the A549 cell line, displayed fibrinolytic activity toward a pure fibrin clot, but only exosomes from MDA-MB-231 cells could degrade a fibrin clot formed in plasma. Increasing the malignant potential of MCF7 cells decreased the thrombotic activity of their MVs but did not alter their fibrinolytic activity. Decreasing the malignant potential of NB4 cells did not alter the thrombotic or fibrinolytic activity of their MVs or exosomes. Finally, the incubation of MDA-MB-231 cell-derived exosomes with A549 cells increased plasmin generation by these cells. Our data indicate that MVs generally have thrombotic activity, whereas thrombotic activity is not commonly observed for exosomes. Furthermore, exosomes and MVs generally do not display fibrinolytic activity under physiological conditions.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 29752284      PMCID: PMC5965050          DOI: 10.1182/bloodadvances.2017015479

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  49 in total

1.  Identification and proteomic profiling of exosomes in human urine.

Authors:  Trairak Pisitkun; Rong-Fong Shen; Mark A Knepper
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

2.  Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.

Authors:  Joanna Kowal; Guillaume Arras; Marina Colombo; Mabel Jouve; Jakob Paul Morath; Bjarke Primdal-Bengtson; Florent Dingli; Damarys Loew; Mercedes Tkach; Clotilde Théry
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

3.  Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.

Authors:  L Zitvogel; A Regnault; A Lozier; J Wolfers; C Flament; D Tenza; P Ricciardi-Castagnoli; G Raposo; S Amigorena
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

Review 4.  Microparticles and Fibrinolysis.

Authors:  Loris Vallier; Sylvie Cointe; Romaric Lacroix; Amandine Bonifay; Coralie Judicone; Françoise Dignat-George; Hau C Kwaan
Journal:  Semin Thromb Hemost       Date:  2016-12-06       Impact factor: 4.180

5.  Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.

Authors:  J Wolfers; A Lozier; G Raposo; A Regnault; C Théry; C Masurier; C Flament; S Pouzieux; F Faure; T Tursz; E Angevin; S Amigorena; L Zitvogel
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

6.  Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines.

Authors:  A Angelucci; S D'Ascenzo; C Festuccia; G L Gravina; M Bologna; V Dolo; A Pavan
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

7.  Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation.

Authors:  Alexandre Semov; Maria J Moreno; Anatoli Onichtchenko; Abedelnasser Abulrob; Marguerite Ball; Irena Ekiel; Grzegorz Pietrzynski; Danica Stanimirovic; Valery Alakhov
Journal:  J Biol Chem       Date:  2005-03-23       Impact factor: 5.157

8.  Plasminogen activator inhibitor (PAI-1) in plasma and platelets.

Authors:  N A Booth; A J Simpson; A Croll; B Bennett; I R MacGregor
Journal:  Br J Haematol       Date:  1988-11       Impact factor: 6.998

9.  Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes.

Authors:  B T Pan; K Teng; C Wu; M Adam; R M Johnstone
Journal:  J Cell Biol       Date:  1985-09       Impact factor: 10.539

Review 10.  Extracellular vesicles: exosomes, microvesicles, and friends.

Authors:  Graça Raposo; Willem Stoorvogel
Journal:  J Cell Biol       Date:  2013-02-18       Impact factor: 10.539

View more
  5 in total

1.  Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling.

Authors:  Yayun Cui; Shu Zhang; Xiaohan Hu; Fei Gao
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  Circulating Extracellular Vesicles Are Strongly Associated With Cardiovascular Risk Markers.

Authors:  Ruihan Zhou; Esra Bozbas; Keith Allen-Redpath; Parveen Yaqoob
Journal:  Front Cardiovasc Med       Date:  2022-05-26

Review 3.  The Multifaceted Role of Plasminogen in Cancer.

Authors:  Beate Heissig; Yousef Salama; Taro Osada; Ko Okumura; Koichi Hattori
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

Review 4.  Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders.

Authors:  Houssam Al-Koussa; Ibrahim AlZaim; Marwan E El-Sabban
Journal:  J Clin Med       Date:  2022-08-22       Impact factor: 4.964

5.  Plasma-derived DNA containing-extracellular vesicles induce STING-mediated proinflammatory responses in dermatomyositis.

Authors:  Yubin Li; Christina Bax; Jay Patel; Thomas Vazquez; Adarsh Ravishankar; Muhammad M Bashir; Madison Grinnell; DeAnna Diaz; Victoria P Werth
Journal:  Theranostics       Date:  2021-05-21       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.